106 related articles for article (PubMed ID: 26986809)
1. Radiation Duration in Women with Cervical Cancer Treated with Primary Chemoradiation: A Population-Based Analysis.
Tergas AI; Neugut AI; Chen L; Burke WM; Hershman DL; Wright JD
Cancer Invest; 2016; 34(3):137-47. PubMed ID: 26986809
[TBL] [Abstract][Full Text] [Related]
2. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
3. HPV genotypes predict survival benefits from concurrent chemotherapy and radiation therapy in advanced squamous cell carcinoma of the cervix.
Wang CC; Lai CH; Huang YT; Chao A; Chou HH; Hong JH
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e499-506. PubMed ID: 22889667
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation.
Kim TE; Park BJ; Kwack HS; Kwon JY; Kim JH; Yoon SC
J Obstet Gynaecol Res; 2012 Nov; 38(11):1315-20. PubMed ID: 22612778
[TBL] [Abstract][Full Text] [Related]
5. Concurrent chemo-irradiation with weekly cisplatin and paclitaxel in the treatment of locally advanced squamous cell carcinoma of cervix: a phase II study.
Varghese SS; Ram TS; Pavamani SP; Thomas EM; Jeyaseelan V; Viswanathan PN
J Cancer Res Ther; 2014; 10(2):330-6. PubMed ID: 25022387
[TBL] [Abstract][Full Text] [Related]
6. Impact of age on receipt of curative treatment for cervical cancer: an analysis of patterns of care and survival in a large, national cohort.
Albert A; Lee A; Allbright R; Vijayakumar S
J Geriatr Oncol; 2019 May; 10(3):465-474. PubMed ID: 30361099
[TBL] [Abstract][Full Text] [Related]
7. The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy.
Song S; Rudra S; Hasselle MD; Dorn PL; Mell LK; Mundt AJ; Yamada SD; Lee NK; Hasan Y
Cancer; 2013 Jan; 119(2):325-31. PubMed ID: 22806897
[TBL] [Abstract][Full Text] [Related]
8. Lymphopenia and its association with survival in patients with locally advanced cervical cancer.
Wu ES; Oduyebo T; Cobb LP; Cholakian D; Kong X; Fader AN; Levinson KL; Tanner EJ; Stone RL; Piotrowski A; Grossman S; Roche KL
Gynecol Oncol; 2016 Jan; 140(1):76-82. PubMed ID: 26571200
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
Lim A; Sia S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
[TBL] [Abstract][Full Text] [Related]
10. High versus low-dose rate brachytherapy for cervical cancer.
Patankar SS; Tergas AI; Deutsch I; Burke WM; Hou JY; Ananth CV; Huang Y; Neugut AI; Hershman DL; Wright JD
Gynecol Oncol; 2015 Mar; 136(3):534-41. PubMed ID: 25575481
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
12. Clinical Role of Adjuvant Chemotherapy after Radical Hysterectomy for FIGO Stage IB-IIA Cervical Cancer: Comparison with Adjuvant RT/CCRT Using Inverse-Probability-of-Treatment Weighting.
Jung PS; Kim DY; Lee SW; Park JY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
PLoS One; 2015; 10(7):e0132298. PubMed ID: 26176626
[TBL] [Abstract][Full Text] [Related]
13. Influence of treatment center and hospital volume on survival for locally advanced cervical cancer.
Wright JD; Huang Y; Ananth CV; Tergas AI; Duffy C; Deutsch I; Burke WM; Hou JY; Neugut AI; Hershman DL
Gynecol Oncol; 2015 Dec; 139(3):506-12. PubMed ID: 26177552
[TBL] [Abstract][Full Text] [Related]
14. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
[TBL] [Abstract][Full Text] [Related]
15. Chemoradiation with concomitant boosts followed by radical surgery in locally advanced cervical cancer: long-term results of the ROMA-2 prospective phase 2 study.
Ferrandina G; Gambacorta A; Gallotta V; Smaniotto D; Fagotti A; Tagliaferri L; Foti E; Fanfani F; Autorino R; Scambia G; Valentini V
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):778-85. PubMed ID: 25585781
[TBL] [Abstract][Full Text] [Related]
16. Data-Derived Treatment Duration Goal for Cervical Cancer: Should 8 Weeks Remain the Target in the Era of Concurrent Chemoradiation?
Hong JC; Foote J; Broadwater G; Sosa JA; Gaillard S; Havrilesky LJ; Chino JP
JCO Clin Cancer Inform; 2017 Nov; 1():1-15. PubMed ID: 30657372
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic factors for central recurrence in patients with locally advanced bulky cervical cancer.
Lee WM; Park SI; Kim BJ; Kim MH; Choi SC; Lee ED; Ryu SY
Eur J Obstet Gynecol Reprod Biol; 2012 Apr; 161(2):219-23. PubMed ID: 22326616
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis.
Yoon HI; Cha J; Keum KC; Lee HY; Nam EJ; Kim SW; Kim S; Kim YT; Kim GE; Kim YB
Radiat Oncol; 2015 Jan; 10():18. PubMed ID: 25582425
[TBL] [Abstract][Full Text] [Related]
19. National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements.
Gill BS; Lin JF; Krivak TC; Sukumvanich P; Laskey RA; Ross MS; Lesnock JL; Beriwal S
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1083-90. PubMed ID: 25216857
[TBL] [Abstract][Full Text] [Related]
20. [Comparative analysis of neoadjuvant therapies in stage Ib2 and IIa2 cervical carcinoma].
Hu JL; Wu LY; Li N; Li XG; Huang MN; Zhang R
Zhonghua Fu Chan Ke Za Zhi; 2012 Jun; 47(6):452-7. PubMed ID: 22932113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
